Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06366308
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-16
First Post:
2024-04-10
Brief Title:
Decade-Long Insights Into Transperineal Prostate Biopsy in a West China Population
Sponsor:
West China Hospital
Organization:
West China Hospital
Study Overview
Official Title:
Decade-Long Insights Into Transperineal Prostate Biopsy in a West China Population Temporal Trend Targeted and Repeat Biopsies and Pathological Characterization Comparative Study - Retrospective Cohort
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Prostate cancer PCa remains one of the most prevalent malignancies affecting men globally The disease spectrum of PCa ranges from indolent tumors which may require minimal to no intervention to aggressive potentially lethal forms The complexity of PCa underscores the critical need for precise diagnostics as early and accurate detection is key to improving patient outcomes and tailoring appropriate treatment strategies There have been remarkable advancements in biopsy technology Significant strides in magnetic resonance imaging MRI especially with the establishment of the Prostate Imaging Reporting and Data System PI-RADS have substantially improved the accuracy of PCa detection The combination of MRI with traditional biopsy methods including MRI-targeted biopsy MRI-TBx and systematic biopsy SBx also marks a major advancement in the field
Despite advances in PCa detection the need for improving diagnostics and in-depth assessment of the latest PBx techniques through extensive longitudinal studies remains critical Besides based on the world health organization WHO classification PCa includes a range of pathological forms beyond the commonly known acinar adenocarcinoma However the prevalence and demographic distribution of non-adenocarcinoma types as well as the characteristics of patients with these rarer forms remain unclear Leveraging PBx records spanning over 10 years and involving 10038 cases this study aims to shed light on temporal trends in PBx positivity the evolving clinical profiles of PCa patients and the differences in clinicopathological characteristics of PCa between Western and Asian populations
Despite advances in PCa detection the need for improving diagnostics and in-depth assessment of the latest PBx techniques through extensive longitudinal studies remains critical Besides based on the world health organization WHO classification PCa includes a range of pathological forms beyond the commonly known acinar adenocarcinoma However the prevalence and demographic distribution of non-adenocarcinoma types as well as the characteristics of patients with these rarer forms remain unclear Leveraging PBx records spanning over 10 years and involving 10038 cases this study aims to shed light on temporal trends in PBx positivity the evolving clinical profiles of PCa patients and the differences in clinicopathological characteristics of PCa between Western and Asian populations
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None